Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT

Hospital Universitario Dr. Jose E. Gonzalez21 enrolled

Overview

Ocular Graft Versus Host Disease (OGVHD) is a serious potential complication of allogeneic bone marrow transplants. The usual treatment is topical cyclosporine but when the treatment is initiated the damage to the lacrimal glands has already taken place. The present study aims to prevent OGVHD in reduced-intensity allogeneic hematopoietic transplants by using topical cyclosporine immediately after the engraftment has been achieved

The patient will start using topical cyclosporine immediately after engraftment has taken place (around day 14-18 after the cell infusion) and will continue to receive it for one year. All \>18 year old patients receiving allogeneic stem cell transplants performed with a reduced intensity conditioning regimen at our center are potential candidates for the study. The purpose of the study is to evaluate the efficacy of topical cyclosporine in prevention of ocular versus graft disease when its use is indicated immediately after the engraftment has occured.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Graft-Versus-Host Disease

Interventions

CyclosporineDRUG

Use of topical cyclosporine (one drop of cyclosporine in each eye, twice a day for 12 months)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who have written consent wishing to participate in the study * Patients who have received an allogeneic stem cell hematopoietic transplants performed with a reduced intensity conditioning regimen * \>18 year old Exclusion Criteria: * \<18 year old * Patients not wishing to participate in the study or have * Patients who have received autologous stem cell hematopoietic transplants * Patients with history of rheumatologic diseases * Patients with a previous diagnosis of dry eye síndrome * Patients with previous eye surgery that disrupts corenal integrity

Locations (1)

Servicio de Hematologia Hospital Universitario Dr Jose Eleuterio Gonzalez

Monterrey, Nuevo León, Mexico

Outcomes

Primary Outcomes

Ocular graft versus host disease is manifested by dry eye syndrome and disruptions in corneal integrity. The study will asses the efficacy of topical cyclosporine for preventing OGVHD manifestations

The patient will start using ocular topical cyclosporine at the day of engraftment (around 14-16 days after cell infusion) and will continue to use it for one year. The following landmarks will be evaluated: 1. First evaluation of a new patient with the ophtalmologist: The patient will be evaluated by a qualified ophtalmologist before the allogeneic stem cell transplant with the following tests: Corneal integrity (yes or no), Schirmer test (mm), tear break up time (seconds). 2. Immediately after engraftment has occured (around 14-16 days after cell infusion) the patient will start using topical cyclosporine and will continue to use it for one year. 3. There will be monthly evaluations with Schirmer test to asses tear quiality and detect dry eye syndrome. 4. Every three months the patient will have a complete optalmologic evaluation as describe before

Time frame: 1 year after engraftment

Secondary Outcomes

Characteristics and clinical presentation of ocular graft versus host disease in patients receiving allogeneic bone marrow transplantation using a reduced intensity conditioning regimen

The secondary outcome of the study is to asses the clinical characteristics of ocular graft versus host disease in patients receiving allogeneic stem cell transplants performed with a reduced intensity conditioning regimen

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.